- Home
- SBRA vs HAE Comparison
SBRA vs HAE Comparison
Compare SBRA & HAE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SBRA | HAE |
|---|---|---|
| Founded | 2010 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 3.9B |
| IPO Year | N/A | 1991 |
Fundamental Metrics
Financial Performance| Metric | SBRA | HAE |
|---|---|---|
| Price | $19.16 | $72.52 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 8 | 9 |
| Target Price | $20.63 | ★ $88.75 |
| AVG Volume (30 Days) | ★ 2.5M | 620.8K |
| Earning Date | 02-18-2026 | 02-05-2026 |
| Dividend Yield | ★ 6.24% | N/A |
| EPS Growth | ★ 78.50 | 42.54 |
| EPS | 0.73 | ★ 3.44 |
| Revenue | $747,056,000.00 | ★ $1,327,850,000.00 |
| Revenue This Year | $6.17 | N/A |
| Revenue Next Year | $5.24 | $6.01 |
| P/E Ratio | $26.41 | ★ $21.01 |
| Revenue Growth | ★ 9.34 | N/A |
| 52 Week Low | $15.60 | $47.32 |
| 52 Week High | $19.97 | $87.32 |
Technical Indicators
Market Signals| Indicator | SBRA | HAE |
|---|---|---|
| Relative Strength Index (RSI) | 51.83 | 31.16 |
| Support Level | $19.21 | $79.06 |
| Resistance Level | $19.49 | $86.11 |
| Average True Range (ATR) | 0.40 | 2.44 |
| MACD | -0.01 | -1.37 |
| Stochastic Oscillator | 56.85 | 5.86 |
Price Performance
Historical ComparisonAbout SBRA Sabra Health Care REIT Inc.
Sabra Health Care REIT Inc is a healthcare facility real estate investment trust. The company operates one segment that owns and invests in healthcare real estate. All of the company's revenue is generated in the United States. Sabra's operations consist of nursing facilities, assisted living centers, and mental health facilities.
About HAE Haemonetics Corporation
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.